DFTX NASDAQ
Definium Therapeutics, Inc.
1W: +5.7%
1M: -3.5%
3M: -12.1%
YTD: +171.8%
1Y: +199.5%
3Y: +1315.3%
5Y: +7.0%
$37.08
+1.40 (+3.92%)
Weekly Expected Move ±8.0%
$30
$33
$36
$39
$41
Credit Risk of going bust: lower than 69% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.9%), Definium Therapeutics, Inc. would be worth roughly what it owes.
Total debt $36.5M against a stock market value of $4.98B.
Distance to default 7.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.2M (short-term plus half of long-term), stock volatility 73.3%; Altman Z'' 6.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.9%), Definium Therapeutics, Inc. would be worth roughly what it owes.
Total debt $36.5M against a stock market value of $4.98B.
Distance to default 7.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.2M (short-term plus half of long-term), stock volatility 73.3%; Altman Z'' 6.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.0B
52W Range12.882-49.2
Volume1,281,899
Avg Volume2,729,822
Beta2.19
Dividend—
Analyst Ratings
Company Info
CEORobert Barrow
Employees106
SectorHealthcare
IndustryBiotechnology
IPO Date2016-11-15
Websitedefiniumtx.com
One World Trade Center
New York, NY 10007
US
New York, NY 10007
US
212 220 6633
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 â an R-enantiomer of 3,4-methylenedioxymethamphetamine â is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Latest News
-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Target Price of $66.00 According to Analysts
Definium Therapeutics (NASDAQ:DFTX) CEO Robert Barrow Sells 31,550 Shares of Company Stock
Definium Therapeutics (NASDAQ:DFTX) Insider Mark Sullivan Sells 14,051 Shares of Stock
Definium Therapeutics (NASDAQ:DFTX) CFO Brandi Roberts Sells 3,377 Shares of Company Stock
Definium Therapeutics (NASDAQ:DFTX) Insider Matthew Wiley Sells 3,097 Shares of Company Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Karlin Daniel | S-Sale | 10,853 | $36.57 | 2026-09-25 |
| Barrow Robert | S-Sale | 31,550 | $36.57 | 2026-09-25 |
| Wiley Matthew T. | S-Sale | 3,097 | $36.57 | 2026-09-25 |
| Sullivan Mark | S-Sale | 14,051 | $36.57 | 2026-09-25 |
| Roberts Brandi | S-Sale | 3,377 | $36.57 | 2026-09-25 |